Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons

scientific article published on January 1996

Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1172/JCI118380
P932PMC publication ID507071
P698PubMed publication ID8550824

P2093author name stringR Vogel
J Eng
D A D'Alessio
J W Ensinck
D Koerker
E Laschansky
R Prigeon
P2860cites workTissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humansQ27865308
Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivoQ27999767
Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serumQ28117412
Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposalQ34147299
Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginineQ34180164
Insulin Secretion in Response to Glycemic Stimulus: Relation of Delayed Initial Release to Carbohydrate intolerance in Mild Diabetes Mellitus*Q34267205
Glucagon-like peptide-1 is a physiological incretin in ratQ34662409
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitusQ35824086
Glucagon-like peptide-1(7-36) amide is a new incretin/enterogastrone candidateQ36396952
Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucoseQ37006231
Glucagon and the glucagon-like peptidesQ37945757
New developments in the incretin conceptQ39832287
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*Q40329405
Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitusQ40342100
Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreasQ40920945
Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.Q41527377
Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C.Q41543796
A simplified, colorimetric micromethod for xylose in serum or urine, with phloroglucinolQ41675896
Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucoseQ41902943
Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action.Q42492827
Glucagon-like peptide 1: a potent glycogenic hormoneQ42496184
Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37).Q42574446
Glucagon-like peptide-1 7-36: a physiological incretin in man.Q43623564
Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4Q43684539
Use of benzamidine as a proteolytic inhibitor in the radioimmunoassay of glucagon in plasmaQ44793381
Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitusQ45306841
Studies of a Simplified Plasma Insulin Immunoassay Using Cellulose PowderQ46429425
Early and late insulin response as predictors of NIDDM in Pima Indians with impaired glucose tolerance.Q51591219
Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion.Q51596078
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.Q51599426
Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.Q51600133
Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.Q51601217
Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjectsQ51606971
Nutrient and hormonal regulation of the threshold of glucose-stimulated insulin secretion in isolated rat pancreases.Q51624645
Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2).Q51630012
The insulin sensitivity index in nondiabetic man. Correlation between clamp-derived and IVGTT-derived values.Q52870668
Glucagonlike peptide 1: a newly discovered gastrointestinal hormoneQ58449144
Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetesQ68145371
Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitusQ68917267
Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amideQ69511007
Intestinal Factors in the Control of Insulin SecretionQ71162152
Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amideQ72390484
Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscleQ72572861
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectglucoseQ37525
glycobiologyQ899224
P304page(s)133-138
P577publication date1996-01-01
P1433published inJournal of Clinical InvestigationQ3186904
P1476titleElimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons
P478volume97

Reverse relations

cites work (P2860)
Q48183718Acute but not chronic activation of brain glucagon-like peptide-1 receptors enhances glucose-stimulated insulin secretion in mice
Q34560507Alpha cell function in health and disease: influence of glucagon-like peptide-1.
Q37174896CNS GLP-1 regulation of peripheral glucose homeostasis
Q37212333Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides
Q36479829Comparison of Bariatric Surgical Procedures for Diabetes Remission: Efficacy and Mechanisms
Q37031078Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, β-cell function, and glucose metabolism in nondiabetic subjects
Q54068522Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice.
Q42136958Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis
Q33869732Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes
Q38356895Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological increti
Q35545683Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Q36846123Exenatide can reduce glucose independent of islet hormones or gastric emptying
Q39801749Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Q40420025Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion
Q43638669Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers
Q44665356Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system
Q35360690GLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modification
Q36249759GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel
Q79387626Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia
Q34401791Glucagon-like peptide 1(GLP-1) in biology and pathology
Q35772029Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes
Q52522147Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.
Q74642726Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide
Q38225693Incretins: their physiology and application in the treatment of diabetes mellitus.
Q47295180Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats.
Q26749196Is GLP-1 a hormone: Whether and When?
Q35624667Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors
Q33184111Local, exendin-(9-39)-insensitive, site of action of GLP-1 in canine ileum
Q44594452Long-term effects of high dietary fiber intake on glucose tolerance and lipid metabolism in GK rats: comparison among barley, rice, and cornstarch
Q33634407Meal-anticipatory glucagon-like peptide-1 secretion in rats.
Q40036350New ways in which GLP-1 can regulate glucose homeostasis
Q34286456Nonhuman primates and other animal models in diabetes research
Q41104121Overexpression of glucagon-like peptide-1 receptor in an insulin-secreting cell line enhances glucose responsiveness
Q26825393Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the Block
Q54046117Properties of native and in vitro glycosylated forms of the glucagon-like peptide-1 receptor antagonist exendin(9-39).
Q37061286Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion
Q42492321Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice
Q36902183The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?
Q33776092The incretin system and cardiometabolic disease
Q37913523The role of dysregulated glucagon secretion in type 2 diabetes
Q35251016The role of gut hormones in glucose homeostasis
Q34901533The role of incretins in glucose homeostasis and diabetes treatment
Q36269671Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches
Q35680897β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity